Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine.

Villa-Pulgarín JA, Gajate C, Botet J, Jimenez A, Justies N, Varela-M RE, Cuesta-Marbán Á, Müller I, Modolell M, Revuelta JL, Mollinedo F.

PLoS Negl Trop Dis. 2017 Aug 22;11(8):e0005805. doi: 10.1371/journal.pntd.0005805. eCollection 2017 Aug.

2.

A newly homozygous variant in ZNF808: A possible candidate gene for Satoyoshi Syndrome?

Solera J, Álvarez S, Botet J, de Cabo C.

J Neurol Sci. 2017 Aug 15;379:226-228. doi: 10.1016/j.jns.2017.06.023. Epub 2017 Jun 16. No abstract available.

PMID:
28716247
3.

Genomic profiling of fungal cell wall-interfering compounds: identification of a common gene signature.

García R, Botet J, Rodríguez-Peña JM, Bermejo C, Ribas JC, Revuelta JL, Nombela C, Arroyo J.

BMC Genomics. 2015 Sep 5;16:683. doi: 10.1186/s12864-015-1879-4.

4.

Chromosome segregation and organization are targets of 5'-Fluorouracil in eukaryotic cells.

Mojardín L, Botet J, Moreno S, Salas M.

Cell Cycle. 2015;14(2):206-18. doi: 10.4161/15384101.2014.974425.

5.

New insights into the RNA-based mechanism of action of the anticancer drug 5'-fluorouracil in eukaryotic cells.

Mojardín L, Botet J, Quintales L, Moreno S, Salas M.

PLoS One. 2013 Nov 1;8(11):e78172. doi: 10.1371/journal.pone.0078172. eCollection 2013.

6.

Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast.

Cuesta-Marbán Á, Botet J, Czyz O, Cacharro LM, Gajate C, Hornillos V, Delgado J, Zhang H, Amat-Guerri F, Acuña AU, McMaster CR, Revuelta JL, Zaremberg V, Mollinedo F.

J Biol Chem. 2013 Mar 22;288(12):8405-18. doi: 10.1074/jbc.M112.425769. Epub 2013 Jan 18.

7.

Genome-wide analysis of factors affecting transcription elongation and DNA repair: a new role for PAF and Ccr4-not in transcription-coupled repair.

Gaillard H, Tous C, Botet J, González-Aguilera C, Quintero MJ, Viladevall L, García-Rubio ML, Rodríguez-Gil A, Marín A, Ariño J, Revuelta JL, Chávez S, Aguilera A.

PLoS Genet. 2009 Feb;5(2):e1000364. doi: 10.1371/journal.pgen.1000364. Epub 2009 Feb 6.

8.

A chemical genomic screen in Saccharomyces cerevisiae reveals a role for diphthamidation of translation elongation factor 2 in inhibition of protein synthesis by sordarin.

Botet J, Rodríguez-Mateos M, Ballesta JP, Revuelta JL, Remacha M.

Antimicrob Agents Chemother. 2008 May;52(5):1623-9. doi: 10.1128/AAC.01603-07. Epub 2008 Feb 19.

9.
10.

Increased efficacy of internal carotid artery stenting using a low-profile stent with a tapered tip.

Choragudi NL, Pucillo AL, Mateo RB, Aronow WS, Botet JF.

Cardiol Rev. 2005 Jan-Feb;13(1):24-6.

PMID:
15596024
11.

Obstructive jaundice in patients receiving hepatic artery infusional chemotherapy: etiology, treatment implications, and complications after transhepatic biliary drainage.

Brown KT, Kemeny N, Berger MF, Getrajdman GI, Napp T, Fong Y, Herman S, Kurtz RC, Botet J, Blumgart LH.

J Vasc Interv Radiol. 1997 Mar-Apr;8(2):229-34. No abstract available.

PMID:
9083989
12.

Clinical observation: congenital absence of the left portal vein in a patient undergoing hepatic resection.

Charny CK, Ling P, Botet J, Blumgart LH.

HPB Surg. 1997;10(5):323-6; discussion 326-7.

13.

Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas.

Kostakoglu L, Panicek DM, Divgi CR, Botet J, Healy J, Larson SM, Abdel-Dayem HM.

Eur J Nucl Med. 1996 Nov;23(11):1558. No abstract available.

PMID:
9044869
14.

New treatment approaches to liver tumors.

Botet JF.

J Nucl Med. 1996 Jun;37(6):963-4. No abstract available.

15.

Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.

Kelsen D, Karpeh M, Schwartz G, Gerdes H, Lightdale C, Botet J, Lauers G, Klimstra D, Huang Y, Saltz L, Quan V, Brennan M.

J Clin Oncol. 1996 Jun;14(6):1818-28.

PMID:
8656250
16.

Malignant hepatic hilar tumors: can ultrasonography be used as an alternative to angiography with CT arterial portography for determination of resectability?

Hann LE, Fong Y, Shriver CD, Botet JF, Brown KT, Klimstra DS, Blumgart LH.

J Ultrasound Med. 1996 Jan;15(1):37-45.

PMID:
8667482
17.
18.

Endoscopic ultrasonography of the gastrointestinal tract.

Botet JF, Lightdale C.

Gastroenterol Clin North Am. 1995 Jun;24(2):385-412. Review.

PMID:
7642249
19.

Clinical trial of the Bard CT guide system.

Brown KT, Getrajdman GI, Botet JF.

J Vasc Interv Radiol. 1995 May-Jun;6(3):405-10.

PMID:
7647442
20.

Identification of blood meals of Phlebotomus perniciosus (Diptera: Psychodidae) in Spain by a competitive enzyme-linked immunosorbent assay biotin/avidin method.

De Colmenares M, Portús M, Botet J, Dobaño C, Gállego M, Wolff M, Seguí G.

J Med Entomol. 1995 May;32(3):229-33.

PMID:
7616511
21.

Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma.

Kemeny N, Conti JA, Cohen A, Campana P, Huang Y, Shi WJ, Botet J, Pulliam S, Bertino JR.

J Clin Oncol. 1994 Nov;12(11):2288-95.

PMID:
7964942
22.

Large gastric folds: a diagnostic approach using endoscopic ultrasonography.

Mendis RE, Gerdes H, Lightdale CJ, Botet JF.

Gastrointest Endosc. 1994 Jul-Aug;40(4):437-41.

PMID:
7926533
23.

Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update.

Kemeny N, Seiter K, Conti JA, Cohen A, Bertino JR, Sigurdson ER, Botet J, Chapman D, Mazumdar M, Budd AJ.

Cancer. 1994 Feb 15;73(4):1134-42.

24.

Preoperative endoscopic ultrasound can predict the risk of recurrence after operation for gastric carcinoma.

Smith JW, Brennan MF, Botet JF, Gerdes H, Lightdale CJ.

J Clin Oncol. 1993 Dec;11(12):2380-5.

PMID:
8246026
25.

Staging of esophageal cancer.

Lightdale CJ, Botet JF.

Endoscopy. 1993 Nov;25(9):655-9. Review. No abstract available.

PMID:
8119226
26.

A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.

Kemeny N, Conti JA, Sigurdson E, Cohen A, Seiter K, Lincer R, Niedzwiecki D, Botet J, Chapman D, Costa P, et al.

Cancer. 1993 Mar 15;71(6):1964-71.

27.

Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer.

Kemeny N, Cohen A, Seiter K, Conti JA, Sigurdson ER, Tao Y, Niedzwiecki D, Botet J, Budd A.

J Clin Oncol. 1993 Feb;11(2):330-5.

PMID:
8426211
28.

Endoscopic ultrasonography of the upper gastrointestinal tract.

Botet JF, Lightdale C.

Radiol Clin North Am. 1992 Sep;30(5):1067-83. Review.

PMID:
1518929
29.

Localization of pancreatic endocrine tumors by endoscopic ultrasonography.

Rösch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, Heyder N, Palazzo L, Dancygier H, Schusdziarra V, et al.

N Engl J Med. 1992 Jun 25;326(26):1721-6.

30.

Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.

Kemeny N, Conti JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W.

J Clin Oncol. 1992 May;10(5):747-52.

PMID:
1569447
31.
32.

A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.

Kemeny N, Seiter K, Niedzwiecki D, Chapman D, Sigurdson E, Cohen A, Botet J, Oderman P, Murray P.

Cancer. 1992 Jan 15;69(2):327-34.

33.

Ultrasound directed extrahepatic bile duct intraluminal brachytherapy.

Minsky B, Botet J, Gerdes H, Lightdale C.

Int J Radiat Oncol Biol Phys. 1992;23(1):165-7.

PMID:
1315312
34.

Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT.

Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Winawer SJ, Urmacher C, Brennan MF.

Radiology. 1991 Nov;181(2):426-32.

PMID:
1924784
35.

Preoperative staging of esophageal cancer: comparison of endoscopic US and dynamic CT.

Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Urmacher C, Brennan MF.

Radiology. 1991 Nov;181(2):419-25.

PMID:
1924783
36.

Localization of endocrine tumors of the pancreas with endoscopic ultrasonography.

Lightdale CJ, Botet JF, Woodruff JM, Brennan MF.

Cancer. 1991 Oct 15;68(8):1815-20.

37.

Extrahepatic biliary system cancer: an update of a combined modality approach.

Minsky BD, Kemeny N, Armstrong JG, Reichman B, Botet J.

Am J Clin Oncol. 1991 Oct;14(5):433-7.

PMID:
1951179
38.

A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.

Crown J, Jakubowski A, Kemeny N, Gordon M, Gasparetto C, Wong G, Sheridan C, Toner G, Meisenberg B, Botet J, et al.

Blood. 1991 Sep 15;78(6):1420-7.

39.

Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.

Crown J, Casper ES, Botet J, Murray P, Kelsen DP.

J Clin Oncol. 1991 Sep;9(9):1682-6.

PMID:
1875224
40.

A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.

Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R.

Cancer. 1991 Sep 1;68(5):965-9.

41.

Mucolytic-antifoam solution for reduction of artifacts during endoscopic ultrasonography: a randomized controlled trial.

Yiengpruksawan A, Lightdale CJ, Gerdes H, Botet JF.

Gastrointest Endosc. 1991 Sep-Oct;37(5):543-6.

PMID:
1657680
42.

Evaluation of submucosal upper gastrointestinal tract lesions by endoscopic ultrasound.

Boyce GA, Sivak MV Jr, Rösch T, Classen M, Fleischer DE, Boyce HW Jr, Lightdale CJ, Botet JF, Hawes RH, Lehman GA.

Gastrointest Endosc. 1991 Jul-Aug;37(4):449-54.

PMID:
1916167
43.

Endoscopic sonography of the upper gastrointestinal tract.

Botet JF, Lightdale C.

AJR Am J Roentgenol. 1991 Jan;156(1):63-8.

PMID:
1898572
44.

Microbiological analysis of sepsis complicating non-surgical biliary drainage in malignant obstruction.

Levine JG, Botet J, Kurtz RC.

Gastrointest Endosc. 1990 Jul-Aug;36(4):364-8.

PMID:
2120104
45.
46.

Combined modality therapy of extrahepatic biliary system cancer.

Minsky BD, Wesson MF, Armstrong JG, Kemeny N, Reichman B, Botet J, Nori D.

Int J Radiat Oncol Biol Phys. 1990 May;18(5):1157-63.

PMID:
2347722
47.

Esophageal carcinoma: pre-operative staging and evaluation of anastomotic recurrence.

Lightdale CJ, Botet JF.

Gastrointest Endosc. 1990 Mar-Apr;36(2 Suppl):S11-6. Review.

PMID:
2184079
48.

Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.

Kemeny N, Israel K, Niedzwiecki D, Chapman D, Botet J, Minsky B, Vinciguerra V, Rosenbluth R, Bosselli B, Cochran C, et al.

J Clin Oncol. 1990 Feb;8(2):313-8.

PMID:
2405107
49.

Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine.

Dougherty JB, Kelsen D, Kemeny N, Magill G, Botet J, Niedzwiecki D.

J Natl Cancer Inst. 1989 Nov 15;81(22):1735-8.

PMID:
2681796
50.

Diagnosis of recurrent upper gastrointestinal cancer at the surgical anastomosis by endoscopic ultrasound.

Lightdale CJ, Botet JF, Kelsen DP, Turnbull AD, Brennan MF.

Gastrointest Endosc. 1989 Sep-Oct;35(5):407-12.

PMID:
2676688

Supplemental Content

Support Center